Furthermore, HER2+ BC cells develop trastuzumab resistance by secreting sEVs that contain the immunosuppressive cytokine TGF-β1 and the lymphocyte activation inhibitor PD-L1 [178]. The gene discussed is ERBB2; the disease is breast cancer.